TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
王金洲WANG, CHIN-CHOU
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
ccwang52@cgmh.org.tw
發表文獻
33筆
11
Tsai YH, Lin CY, Chen YM, Chang YP, Hung KY, Chang YC, et al. Impact of Body Mass Index on the Survival of Patients with Sepsis with Different Modified NUTRIC Scores. Nutrients. 2021;13(6).
12
Wang CC, Chiu LC, Ju JS, Lin YC, Fang YF, Yang CT, et al. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines (Basel). 2021;9(10).
13
Wang CC, Chiu LC, Tung PH, Kuo SC, Chu CH, Huang AC, et al. A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. Oncol Ther. 2021;9(2):489-503. (ESCI)
14
Wang CC, Lai CH, Chang YP, Chang HC, Tseng CC, Huang KT, et al. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. Thorac Cancer. 2021;12(23):3263-72.
15
Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, et al. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer. 2022;13(1):38-47
16
Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. J Thorac Oncol. 2022;17(3):411-22.
17
Chen CZ, Sheu CC, Cheng SL, Wang HC, Lin MC, Hsu WH, et al. Performance and Clinical Utility of Various Chronic Obstructive Pulmonary Disease Case-Finding Tools.
18
Pan HY, Cheng FJ, Huang KC, Kung CT, Huang WT, You HL, et al. Exposure to tris(2-butoxyethyl) phosphate induces abnormal sperm morphology and testicular histopathology in male rats. Ecotoxicol Environ Saf. 2022;241:113718.
19
Wu CC, Wang CC, Chung WY, Sheu CC, Yang YH, Cheng MY, et al. Environmental risks and sphingolipid signatures in adult asthma and its phenotypic clusters: a multicentre study. Thorax. 2022
20
Wu SG, Chiang CL, Wang CC, Hung JY, Hsia TC, Kuo CH, et al. Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. J Cancer. 2022;13(9):2922-32
